Neurovation Labs Awarded Additional Air Force Phase II Contract Worth $1.25M to Develop Tools to Mitigate PTSD and Other Brain Traumas

NEW YORK, June 21, 2022 /PRNewswire/ -- Neurovation Labs, Inc., a biotechnology company developing the first objective diagnostic and companion treatment for Post-traumatic Stress Disorder (PTSD), today announced that it has been awarded a second U.S. Air Force Small Business Innovation Research (SBIR) Direct to Phase II contract through AFWERX and Air Force Research Lab (AFRL). This contract follows a Phase I contract in December 2019 and a Phase II contract in June 2020, where the company gained the sponsorship of the Air Force Special Operations Command (AFSOC) 24th Special Operations Wing to continue development of the PTSD diagnostic and treatment. This Phase II contract will significantly accelerate the development of these pivotal healthcare technologies, as well as explore expansion into detecting Traumatic Brain Injury (TBI), including mild TBI (mTBI).